| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Ribocil-C is a novel, potenty and highly selective chemical modulator of bacterial riboflavin riboswitches. Ribocil-C strongly inhibits GFP expression, achieving a 50% effective concentration (EC50) of 0.3 μM. Ribocil-C is a highly specific bioactive synthetic mimic of FMN, which competes with the natural ligand to inhibit FMN riboswitch-mediated expression of ribB and inhibits bacterial growth. Riboswitches are non-coding RNA structures located in messenger RNAs that bind endogenous ligands, such as a specific metabolite or ion, to regulate gene expression. As such, riboswitches serve as a novel, yet largely unexploited, class of emerging drug targets. Demonstrating this potential, however, has proven difficult and is restricted to structurally similar antimetabolites and semi-synthetic analogues of their cognate ligand, thus greatly restricting the chemical space and selectivity sought for such inhibitors.
| Targets |
Bacterial riboflavin riboswitches
|
|---|---|
| ln Vitro |
The flavin mononucleotide (FMN) riboswitch, which regulates the expression of de novo riboflavin (RF, vitamin B2) biosynthesis in Escherichia coli, is highly selectively inhibited by ribocil-C. In order to independently regulate the RF biosynthesis and uptake processes necessary for Staphylococcus aureus growth and pathogenesis, riboflavin-C specifically inhibits dual FMN riboswitches[1]. In order to inhibit ribB expression and RF synthesis, which in turn stops bacterial growth, Ribocil-C, a synthetic small-molecule FMN mimic, binds the FMN riboswitch of several GN bacteria, such as Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii[1][2].
|
| ln Vivo |
Increased dosage In comparison to sham-treated mice, the ribocil-C treatment groups (60 and 120 mg kg21 ribocil-C) show a dose-dependent reduction in bacterial burden of 1.87 and 3.29 log10[CFU per g spleen] reduction, respectively, without mortality or obvious toxicity effects[2].
|
| Animal Protocol |
Intraperitoneal injection of Escherichia coli strain MB5746 (5×104 CFU/mouse) is used to infect DBA/2J mice. The infection is treated with three subcutaneous injections of either ciprofloxacin (0.5 mg/kg) or Ribocil-C (30, 60, 120 mg/kg) over a 24-hour period. Five mice per group have their spleens aseptically removed, and the reduction of log[CFU per g spleen tissue] is computed based on the amount of bacteria present in the spleens of the control group that received a 10% DMSO treatment[2].
|
| References |
| Molecular Formula |
C21H21N7OS
|
|---|---|
| Molecular Weight |
419.5027
|
| Exact Mass |
419.15
|
| Elemental Analysis |
C, 60.13; H, 5.05; N, 23.37; O, 3.81; S, 7.64
|
| CAS # |
1825355-56-3
|
| Related CAS # |
Ribocil;1381289-58-2;Ribocil-C (R enantiomer);2177266-81-6;Ribocil B;1825355-55-2;Ribocil-C Racemate;2309762-18-1
|
| Appearance |
Solid powder
|
| SMILES |
O=C1NC([C@@H]2CN(CC3=CN(C4=NC=CC=N4)C=N3)CCC2)=NC(C5=CC=CS5)=C1
|
| InChi Key |
UVDVCDUBJWYRJW-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C21H21N7OS/c29-19-10-17(18-5-2-9-30-18)25-20(26-19)15-4-1-8-27(11-15)12-16-13-28(14-24-16)21-22-6-3-7-23-21/h2-3,5-7,9-10,13-15H,1,4,8,11-12H2,(H,25,26,29)/t15-/m0/s1
|
| Chemical Name |
2-[(3S)-1-[[1-(2-Pyrimidinyl)-1H-imidazol-4-yl]methyl]-3-piperidinyl]-6-(2-thienyl)-4(3H)-pyrimidinone
|
| Synonyms |
Ribocil-C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~110 mg/mL (~262.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (6.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (6.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 10% DMSO+90% Corn Oil: ≥ 2.75 mg/mL (6.56 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3838 mL | 11.9190 mL | 23.8379 mL | |
| 5 mM | 0.4768 mL | 2.3838 mL | 4.7676 mL | |
| 10 mM | 0.2384 mL | 1.1919 mL | 2.3838 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA